Over the past decade, NIDCR has invested in the development of specimens and preclinical models of salivary gland cancers, as well as their genomic characterization. The field is now ripe for translating the significantly expanded basic biological understanding and preclinical models into new therapeutics. Phenotypic and target-based drug discovery can lead to rational clinical trials for these tumor types which have no FDA-approved systemic therapies.
Comment No. 115